Get the Stockscreener App
88.24
1.44%
-1.51
Dexcom Inc stock is traded at $88.24, with a volume of 1.12M.
It is down -1.44% in the last 24 hours and up +15.40% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$89.75
Open:
$89.34
24h Volume:
1.12M
Relative Volume:
0.20
Market Cap:
$33.28B
Revenue:
$4.82B
Net Income/Loss:
$930.40M
P/E Ratio:
37.74
EPS:
2.3381
Net Cash Flow:
$1.43B
1W Performance:
+0.92%
1M Performance:
+15.40%
6M Performance:
+25.59%
1Y Performance:
+9.27%
1-Day Range:
$88.14
$89.90
1-Week Range:
$87.06
$91.96
52-Week Range:
$54.11
$91.96
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
88.19 | 33.87B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
110.09 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
331.95 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.59 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.51 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.72 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Nippon Life Global Investors Americas Inc. Buys Shares of 53,400 DexCom, Inc. $DXCM - MarketBeat
DexCom (DXCM) Stock Sees Modest Fair Value Lift After Q2 And Clinical Updates - Yahoo Finance
DexCom Inc (MIL:1DXCM) Stock Price, Trades & News - GuruFocus
Bridgewater Advisors Inc. Invests $1.08 Million in DexCom, Inc. $DXCM - MarketBeat
43,005 Shares in DexCom, Inc. $DXCM Bought by SWS Partners - MarketBeat
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Is Wall Street Bullish or Bearish on DexCom Stock? - Barchart.com
Dexcom Inc (DXCM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dexcom (DXCM) director Augustinos donates 1,075 shares and reports 5,575 RSUs - Stock Titan
ETFs Investing in DexCom, Inc. Stocks - TradingView
Dexcom stock holds above $90 as strong Q2 2026 margins support a raised outlook - AD HOC NEWS
Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago - Yahoo Finance
Citigroup Adjusts Price Target on DexCom to $105 From $88, Maintains Buy Rating - marketscreener.com
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches? - TradingView
DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026? - TradingView
DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here? - TradingView
DexCom (DXCM) director Bridgette Heller sells 1,012 shares in planned trade - Stock Titan
E. Ohman J or Asset Management AB Has $7.62 Million Position in DexCom, Inc. $DXCM - MarketBeat
Stronger Q2 Results and Higher 2026 Outlook Might Change The Case For Investing In DexCom (DXCM) - Sahm
DexCom stock hits 52-week high at 87.85 USD By Investing.com - Investing.com UK
DexCom Inc (DXCM) Stock Up 3.4% and Still Undervalued -- GF Scor - GuruFocus
DexCom (NASDAQ:DXCM) Reaches New 1-Year HighWhat's Next? - MarketBeat
DexCom stock hits 52-week high at 87.85 USD - Investing.com
DexCom, Inc. (DXCM) Stock Analysis: Exploring The 10.25% Potential Upside For Investors - directorstalkinterviews.com
Assenagon Asset Management S.A. Has $46.72 Million Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Stock Position Lifted by Gradient Investments LLC - MarketBeat
DexCom, Inc. $DXCM Shares Sold by Pacer Advisors Inc. - MarketBeat
Beacon Investment Advisory Services Inc. Reduces Stake in DexCom, Inc. $DXCM - MarketBeat
Dexcom Inc (DXCM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
DXCM|Dexcom Inc|Price:84.750|Chg%:+1.730 - TradingKey
DexCom Inc. Stock Sheds 4.9%, Underperforms Market - webull.com
DexCom, Inc. (NASDAQ:DXCM) Given Consensus Rating of "Moderate Buy" by Brokerages - marketbeat.com
DexCom Inc (DXCM) Shares Fall 4.9% -- What GF Score of 94 Tells Investors - GuruFocus
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DexCom, Inc. (DXCM) Stock Forecasts - Yahoo! Finance Canada
Rathbones Group PLC Reduces Holdings in DexCom, Inc. $DXCM - MarketBeat
Edgestream Partners L.P. Has $981,000 Holdings in DexCom, Inc. $DXCM - marketbeat.com
DexCom, Inc. (DXCM) Stock forecasts - Yahoo Finance Singapore
DexCom (NASDAQ:DXCM) Director Mark Foletta Sells 2,000 Shares - MarketBeat
DexCom Inc (DXCM) director’s family trust sells 4,000 shares under 10b5-1 plan - Stock Titan
Class Action Alert: Levi & Korsinsky Reminds DexCom (DXCM) Investors of December 26, 2025 Deadline - The National Law Review
Levi & Korsinsky Urges DexCom (DXCM) Shareholders to Act Before Lead Plaintiff Deadline December 26, 2025 - The National Law Review
Argus Adjusts Price Target on DexCom to $96 From $86, Maintains Buy Rating - marketscreener.com
DEXCOM INC : ARGUS RESEARCH RAISES TARGET PRICE BY $10 TO $96 - Bitget
Dexcom Inc : Argus Research Raises Target Pri - Moomoo
DexCom (NASDAQ:DXCM) Stands Out as an Affordable Growth Stock - ChartMill
DexCom Inc (DXCM) Stock Up 4.6% and Still Undervalued -- GF Scor - GuruFocus
Levi & Korsinsky Notifies DexCom, Inc. (DXCM) Shareholders of Cla - The National Law Review
Insider Selling: DexCom (NASDAQ:DXCM) Director Sells 2,000 Shares - MarketBeat
Dexcom Announces Governance Enhancements Ahead of 2026 Investor Day - The National Law Review
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dexcom Inc Stock (DXCM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Heller Bridgette P | Director |
Aug 12 '26 |
Sale |
88.29 |
1,012 |
89,349 |
29,570 |
2.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):